The Foundation has begun three initiatives led by Steering Committees of leading experts in the fields of health economics, public policy, communications, market access, manufacturing, precision medicine, and patient advocacy. These three programs are:
Gene Medicine Education Program
This multi-year program began in 2018 with extensive market research on public and patient/caregiver perceptions and attitudes about gene medicine. It will provide the public with accurate, jargon-free information about the science, benefits, limitations, and possible risks of therapeutic gene medicine technology and encourage news and social media influencers to cover gene medicine in a more balanced way with less emphasis on the sensational.
Planned program activities and content include:
- Compelling, clear illustrations that summarize the science
- Science briefings for journalists and policymakers
- Fact sheets and information kits for patient advocacy groups and medical societies
- Social media campaign on the value of gene medicine
- Public service announcements
- Speaking engagements and calls to participate in conferences and events
Economic Impact Project
The Foundation will conduct research that provides in-depth analyses of the impact of regenerative medicines on national and international healthcare economies. It also is planning to do a pharmaco-economic analysis using advanced economic simulation models of regenerative medicines in several major disease areas to quantify the value of curative therapies compared to the current standard of care.
Industrialization of Gene and Cell Therapies
This research project will identify and prioritize the infrastructure, logistics, and healthcare system requirements essential to support widespread adoption of these transformative medicines. It will explore in depth the components of these therapeutic platforms and how they could leverage manufacturing breakthroughs while integrating technologies such as next-gen sequencing, and other precision medicine tools in imaging and healthcare IT.
ARM Foundation Board of Directors
Founder, Global Genes
Consultant, DLG Strategic Communication
Partner, NDA Partners, LLC
Chief Commercial Officer, bluebird bio
Founder and CEO, Lyfebulb
Executive Director, debra of America
VP Operations, ARM
Head of Marketing and Communications, Inova Health Systems
Managing Director and Head of R&D Strategy Solutions, IQVIA
President & CEO, CIRM
Formerly of Audentes
Principal, Parker BioConsulting
Founder, Senior Advisor, Aisling Partners
Executive Director, Harvard Stem Cell Institute
SVP, Head of Manufacturing, Sigilon Therapeutics, Inc.
Executive Director, ARM Foundation
Hyman, Phelps and McNamara
Stem for Life Foundation and CURA Foundation
Jennifer Mound Smoter
SVP, External Affairs & Communications, Intellia Therapeutics
MD, National Children’s Medical Center, NORD Board Chair
General Manager, Cell Therapy, GE Healthcare Life Sciences
CEO, Akron Biotech
To learn more about the ARM Foundation, including partnerships and opportunities to support its programs, please contact Morrie Ruffin, email@example.com.
(608) 850 4745